Apollo Therapeutics, a Cambridge, UK-, Boston, MA and Chicago, IL-based portfolio biopharmaceutical company, raised $226.5M in Series C funding.
The round was led by Patient Square Capital, with participation from new investors including M&G plc along with existing investor Rock Springs Capital.
The company intends to use the funds to (i) advance pipeline programs through clinical development and further fund its drug discovery and development activities based on breakthroughs in basic medical research made at its partner institutions, and to (ii) licence or acquire additional clinical stage programs that meet strict selection criteria.
Led by Dr. Richard Mason, CEO, Apollo Therapeutics is a portfolio biopharmaceutical company focused on translating fundamental medical research into medicines. The portfolio-model is built around a centralized management team of capital allocators and functional leaders with expertise in pharmaceutical R&D, manufacturing, commercial strategy, fund-raising, and business development, leveraged over a diverse portfolio of therapeutic programs, each led by a dedicated asset leader. Assets are housed in separate wholly owned subsidiary companies.
Current partner institutions are: The University of Cambridge, Imperial College London, University College London, King’s College London, and The Institute of Cancer Research.
Apollo has operations in Cambridge, UK, and Boston and Chicago, USA.
FinSMEs
08/09/2023